Mirum Pharmaceuticals (MIRM) AI Stock Analysis

• Market Cap: $3.73B
• Dividend Yield: N/A
• Average Volume (3M): 640.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: 62.33%
• EPS Growth: 48.34%
• Country: US
• Employees: 334
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 50,237,648
• 10 Day Avg. Volume: 873,286
• 30 Day Avg. Volume: 640,739
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 5.93
• Enterprise Value/Gross Profit: 7.50
• Enterprise Value/Ebitda: -135.43
• 1Y Price Target: $80.80
• Price Target Upside: 8.89% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 58 Neutral
• Price Target: $74.00 ▼(-0.27% Downside)

Mirum Pharmaceuticals' strong revenue growth and positive earnings call are offset by financial challenges and valuation concerns. The technical analysis indicates strong momentum, but potential overbought conditions suggest caution.

Positive Factors

Financial performance

Mirum Pharmaceuticals is recognized for having a cash-flow positive, high-growth commercial business with multiple credible growth opportunities.

Product approval

Livmarli's approval in Japan for Alagille syndrome and progressive familial intrahepatic cholestasis led to a favorable pricing adjustment.

Revenue growth

Rapid growth in Livmarli revenues has surpassed management’s expectations, driven primarily by new patient identification.

Negative Factors

Market competition

Even with competition, volixibat is seen as well-positioned in large rare diseases, with its potential to differentiate on efficacy and benefit from market developments.

Product differentiation

Livmarli's oral tablet formulation could narrow the competitive gap in PFIC new patient starts.

Mirum Pharmaceuticals Business Overview & Revenue Model

Company Description

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

How the Company Makes Money

Mirum Pharmaceuticals generates revenue primarily through the sale of its approved products, including Maralixibat, which is marketed to healthcare providers for the treatment of cholestatic liver diseases. The company also engages in strategic partnerships and collaborations with other pharmaceutical firms to enhance its research and development capabilities, which can lead to milestone payments and royalties based on the success of its partnered programs. Additionally, Mirum may benefit from government grants or incentives aimed at supporting research in rare diseases, contributing to its overall revenue streams.

Mirum Pharmaceuticals Financial Statement Overview

Summary

Mirum Pharmaceuticals is experiencing rapid revenue growth, yet it continues to face profitability challenges as indicated by negative net income and EBIT. The balance sheet shows improved equity positions, but high leverage remains a concern. Negative cash flows highlight liquidity risks, although there are signs of operational improvement. Overall, while the company shows promising growth potential, it faces significant financial stability and profitability challenges.

Income Statement

Mirum Pharmaceuticals has shown significant revenue growth over the years, with TTM revenue at $379.3 million compared to $19.1 million in 2021. However, the company is still reporting negative net income, with a TTM net income of -$77.3 million. Gross profit margins remain strong at 77.1% TTM but the company struggles with negative EBIT and EBITDA margins due to high operational costs.

Balance Sheet

The balance sheet shows a stable equity position with a TTM stockholders' equity of $233.3 million. The debt-to-equity ratio is relatively high at 1.36, indicating significant leverage. However, the equity ratio is 33.8%, suggesting a moderate level of equity financing. The company faces challenges with liabilities exceeding assets in previous years but has improved its balance sheet recently.

Cash Flow

The company's cash flow from operations is negative at -$6.8 million TTM, indicating potential challenges in generating cash internally. Free cash flow is also negative, impacting liquidity. However, there is a positive trend in operating cash flow to net income ratio, showing some operational improvements compared to past years.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	429.16M	336.89M	186.37M	77.06M	19.14M	0.00
Gross Profit	339.14M	255.25M	139.34M	64.69M	17.23M	-623.00K
EBITDA	-18.79M	-48.97M	-136.49M	-122.41M	-65.39M	-102.31M
Net Income	-58.56M	-87.94M	-163.41M	-135.66M	-83.99M	-103.27M
Balance Sheet
Total Assets	725.83M	670.75M	646.62M	352.91M	294.65M	240.86M
Cash, Cash Equivalents and Short-Term Investments	304.55M	280.31M	286.33M	251.72M	156.54M	231.82M
Total Debt	318.90M	317.76M	308.14M	2.19M	2.61M	3.26M
Total Liabilities	470.67M	445.11M	397.95M	210.87M	174.44M	68.77M
Stockholders Equity	255.16M	225.64M	248.67M	-392.82M	120.21M	-173.17M
Cash Flow
Free Cash Flow	-1.37M	9.33M	-91.05M	-120.41M	-151.78M	-89.30M
Operating Cash Flow	8.99M	10.32M	-70.94M	-120.14M	-132.76M	-89.08M
Investing Cash Flow	-40.13M	-90.13M	-107.20M	7.70M	48.55M	37.87M
Financing Cash Flow	24.25M	17.70M	336.60M	109.09M	73.47M	181.29M

Mirum Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 74.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MIRM, the sentiment is Positive. The current price of 74.2 is above the 20-day moving average (MA) of 62.29, above the 50-day MA of 55.72, and above the 200-day MA of 47.55, indicating a bullish trend. The MACD of 5.11 indicates Negative momentum. The RSI at 81.97 is Negative, neither overbought nor oversold. The STOCH value of 96.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MIRM.

Mirum Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPRX	75 Outperform	$2.44B	12.10	28.49%	―	28.55%	196.96%
MIRM	58 Neutral	$3.73B	―	-24.19%	―	62.33%	48.34%
APLS	58 Neutral	$3.53B	―	-108.49%	―	20.02%	33.45%
ARWR	54 Neutral	$2.93B	―	-34.80%	―	2816.21%	73.33%
RARE	54 Neutral	$2.85B	―	-182.60%	―	26.77%	24.18%
Sector *	51 Neutral	$7.83B	-0.15	-40.10%	2.29%	21.46%	-2.01%
IBRX	46 Neutral	$2.25B	―	78.99%	―	4227.22%	50.80%

Mirum Pharmaceuticals Corporate Events

Mirum Pharmaceuticals Holds 2025 Annual Stockholders Meeting

On May 29, 2025, Mirum Pharmaceuticals held its 2025 Annual Meeting of Stockholders, where key decisions were made. Stockholders elected three Class III directors to serve until 2028, ratified Ernst & Young LLP as the independent public accounting firm for 2025, and approved executive compensation, indicating continued support for the company’s leadership and strategic direction.